|
||||||
Executive Summary Eisai Co Ltd (4523)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description-A detailed description of the company's operations and business divisions. - Corporate strategy-Analyst's summarization of the company's business strategy. - SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats. - Company history-Progression of key events associated with the company. - Major products and services-A list of major products, services and brands of the company. - Key competitors-A list of key competitors to the company. - Key employees-A list of the key executives of the company. - Executive biographies-A brief summary of the executives' employment history. - Key operational heads-A list of personnel heading key departments/functions. - Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities-A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company's franchise areas in research include neurology and oncology. Eisai's major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer's agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan. Eisai Co Ltd Key Recent Developments Jul 27,2018: AAIC 2018 introduces first clinical trial showing intensive blood pressure therapy reduces new cases of mild cognition and dementia Jul 19,2018: PhoenixBio provides results from studies using PXB-Mouse and PXB-cells being presented at ISSX 2018 Jul 18,2018: Eisai supports relief efforts for flooding in western Japan Jul 04,2018: Eisai Listed For 17th Consecutive Year In FTSE4GOOD Index Series, An Index For Socially Responsible Investment Jun 13,2018: Eisai To Establish New Research Facility Eisai Center For Genetics Guided Dementia Discovery In Cambridge, Massachusetts In The United States Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted. Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios. Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Note: Some sections may be missing if data is unavailable for the company Read More Contact Us:
Table of Contents Table of Contents 3 List of Tables 5 List of Figures 5 Section 1-About the Company 6 Eisai Co Ltd-Key Facts 6 Eisai Co Ltd-Key Employees 7 Eisai Co Ltd-Key Employee Biographies 10 Eisai Co Ltd-Major Products and Services 11 Eisai Co Ltd-History 13 Eisai Co Ltd-Company Statement 21 Eisai Co Ltd-Locations And Subsidiaries 22 Head Office 22 Other Locations & Subsidiaries 22 Joint Venture 25 Section 2-Company Analysis 26 Company Overview 26 Eisai Co Ltd-Business Description 27 Product Category: Neurology Products 27 Overview 27 Performance 27 Product Category: Oncology Products 27 Overview 27 Performance 27 Product Category: Others 28 Performance 28 Product Category: Americas Pharmaceutical Business 28 Overview 28 Performance 28 Product Category: Asia and Latin America Pharmaceutical Business 28 Overview 28 Performance 28 Product Category: China Pharmaceutical Business 29 Overview 29 Performance 29 Product Category: EMEA Pharmaceutical Business 29 Overview 29 Performance 29 Product Category: Japan Pharmaceutical Business 29 Overview 29 Performance 29 Product Category: Other Business 29 Overview 29 Performance 30 R&D Overview 30 Eisai Co Ltd-Corporate Strategy 31 Eisai Co Ltd-SWOT Analysis 32 SWOT Analysis-Overview 32 Eisai Co Ltd-Strengths 32 Eisai Co Ltd-Weaknesses 33 Eisai Co Ltd-Opportunities 34 Eisai Co Ltd-Threats 35 Eisai Co Ltd-Key Competitors 36 Section 3-Company Financial Ratios 37 Financial Ratios-Capital Market Ratios 37 Financial Ratios-Annual Ratios 38 Performance Chart 41 Financial Performance 41 Financial Ratios-Interim Ratios 42 Financial Ratios-Ratio Charts 43 Section 4-Company's Lifesciences Financial Deals and Alliances 44 Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 44 Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 45 Eisai Co Ltd, Recent Deals Summary 46 Section 5-Company's Recent Developments 47 Jul 27, 2018: AAIC 2018 introduces first clinical trial showing intensive blood pressure therapy reduces new cases of mild cognition and dementia 47 Jul 19, 2018: PhoenixBio provides results from studies using PXB-Mouse and PXB-cells being presented at ISSX 2018 51 Jul 18, 2018: Eisai supports relief efforts for flooding in western Japan 52 Jul 04, 2018: Eisai Listed For 17th Consecutive Year In FTSE4GOOD Index Series, An Index For Socially Responsible Investment 53 Jun 13, 2018: Eisai To Establish New Research Facility Eisai Center For Genetics Guided Dementia Discovery In Cambridge, Massachusetts In The United States 54 Jun 13, 2018: Eisai To Establish New Research Facility Eisai Center For Genetics Guided Dementia Discovery In Cambridge, Massachusetts In The United States 55 Jun 13, 2018: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research Using Novel Nucleic Acid Synthesis And Delivery Technologies Concluded 56 Feb 26, 2018: Launch of Dementia Support Insurance to Provide for Dementia in Japan 57 Feb 20, 2018: EISAI Certified In 2018 As Outstanding Health And Productivity Management Organization (WHITE 500) 58 Feb 20, 2018: EISAI Certified In 2018 As Outstanding Health And Productivity Management Organization (WHITE 500) 59 Section 6-Appendix 60 Methodology 60 Ratio Definitions 60 About GlobalData 64 Contact Us 64 Disclaimer 64 List of Figures Eisai Co Ltd, Performance Chart (2014-2018) 41 Eisai Co Ltd, Ratio Charts 43 Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 44 Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 45 List of Tables Eisai Co Ltd, Key Facts 6 Eisai Co Ltd, Key Employees 7 Eisai Co Ltd, Key Employee Biographies 10 Eisai Co Ltd, Major Products and Services 11 Eisai Co Ltd, History 13 Eisai Co Ltd, Subsidiaries 22 Eisai Co Ltd, Joint Venture 25 Eisai Co Ltd, Key Competitors 36 Eisai Co Ltd, Ratios based on current share price 37 Eisai Co Ltd, Annual Ratios 38 Eisai Co Ltd, Annual Ratios (Cont...1) 39 Eisai Co Ltd, Annual Ratios (Cont...2) 40 Eisai Co Ltd, Interim Ratios 42 Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 44 Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 45 Eisai Co Ltd, Recent Deals Summary 46 Currency Codes 60 Capital Market Ratios 60 Equity Ratios 61 Profitability Ratios 61 Cost Ratios 62 Liquidity Ratios 62 Leverage Ratios 63 Efficiency Ratios 63 Single User License: Site License: Corporate User License: Astellas Pharma Inc Chugai Pharmaceutical Co Ltd Daiichi Sankyo Inc Mochida Pharmaceutical Co Ltd Nippon Kayaku Co Ltd Ono Pharmaceutical Co Ltd Takeda Pharmaceutical Co Ltd Eisai Co Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts |
select a license |
||
NEWSLETTER BY CATEGORY
|
||
Testimonials
|
||
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara" |